Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmeet C Singh

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Expert Opinion on Drug Metabolism & Toxicology|May 6, 2015
Effect of age on drug metabolism in women with breast cancerJasmeet C Singh, Stuart M Lichtman
The Oncologist|August 19, 2018
In ReplyChau T Dang, Jasmeet C Singh, Richard M Steingart, et al.
The Oncologist|March 26, 2017
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast CancerAnthony F Yu, Jasmeet C Singh, Rui Wang, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Expert Opinion on Drug Metabolism & Toxicology|May 6, 2015
Effect of age on drug metabolism in women with breast cancerJasmeet C Singh, Stuart M Lichtman
The Oncologist|August 19, 2018
In ReplyChau T Dang, Jasmeet C Singh, Richard M Steingart, et al.
The Oncologist|March 26, 2017
Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast CancerAnthony F Yu, Jasmeet C Singh, Rui Wang, et al.
The Oncologist|February 8, 2017
Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center ExperienceJasmeet C Singh, Anita Mamtani, Andrea Barrio, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Pageof 1